阳光肺科

 找回密码
 立即注册

微信扫码登录

搜索

[可手术有驱动] NEOTIDE/CTONG2104:EGFR敏感突变NSCLC新辅助PD-1抑制剂联合化疗

  [复制链接]
杨学宁医师 发表于 2023-9-10 10:48:36 | 显示全部楼层 |阅读模式

马上注册,阅读更多内容,享用更多功能!

您需要 登录 才可以下载或查看,没有账号?立即注册

×
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)

The clinical efficacy of neoadjuvant immunotherapy plus chemotherapy remains elusive in localized epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Here, we report interim results of a Simon's two-stage design, phase 2 trial using neoadjuvant sintilimab with carboplatin and nab-paclitaxel in resectable EGFR-mutant NSCLC. All 18 patients undergo radical surgery, with one patient experiencing surgery delay. Fourteen patients exhibit confirmed radiological response, with 44% achieving major pathological response (MPR) and no pathological complete response (pCR). Similar genomic alterations are observed before and after treatment without influencing the efficacy of subsequent EGFR-tyrosine kinase inhibitors (TKIs) in vitro. Infiltration and T cell receptor (TCR) clonal expansion of CCR8+ regulatory T (Treg)hi/CXCL13+ exhausted T (Tex)lo cells define a subtype of EGFR-mutant NSCLC highly resistant to immunotherapy, with the phenotype potentially serving as a promising signature to predict immunotherapy efficacy. Informed circulating tumor DNA (ctDNA) detection in EGFR-mutant NSCLC could help identify patients nonresponsive to neoadjuvant immunochemotherapy. These findings provide supportive data for the utilization of neoadjuvant immunochemotherapy and insight into immune resistance in EGFR-mutant NSCLC.

1.更新的EGFR突变人群免疫化疗新辅助MPR(34.1%)/pCR(11.4%)以及中位EFS数据(25.3m),L858R相比19del具有相对更好response rate和survival;
2.不同新辅助治疗多队列genomic数据提示RB1或RBM10共突变更可能从免疫联合化疗模式中获益;
3.EGFR突变新辅助免疫化疗后主要以远处复发进展为主,且免疫化疗不影响复发后靶向治疗疗效及安全性,新辅化免序贯辅助Osi不会带来显著安全性问题,肝损较ADAURA队列增高但无显著性。

文献来源:

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)
Zhang C, Sun YX, Yi DC, Jiang BY, Yan LX, Liu ZD, Peng LS, Zhang WJ, Sun H, Chen ZY, Wang DH, Peng D, Chen SA, Li SQ, Zhang Z, Tan XY, Yang J, Zhao ZY, Zhang WT, Su J, Li YS, Liao RQ, Dong S, Xu CR, Zhou Q, Yang XN, Wu YL, Zhang ZM, Zhong WZ. Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). Cell Rep Med. 2024 Jul 16;5(7):101615. doi: 10.1016/j.xcrm.2024.101615. Epub 2024 Jun 18. PMID: 38897205; PMCID: PMC11293361.
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104): Cell Reports Medicine



Study Details | Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC | ClinicalTrials.gov
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104) - PubMed (nih.gov)
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104) - ScienceDirect
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104) (cell.com)
176.… | The American Association for Thoracic Surgery | AATS
lus 发表于 2024-6-29 21:03:16 | 显示全部楼层

Cell Reports Medicine, IF:14.3丨新辅助免疫联合化疗或将有效治疗EGFR突变NSCLC

游客,您所在的用户组(游客)暂无权限查看回复内容,请微信注册本站
关注抗肿瘤药发展和推广
阳光肺科 发表于 2024-6-29 21:06:02 | 显示全部楼层
游客,您所在的用户组(游客)暂无权限查看回复内容,请微信注册本站
maise 发表于 2024-7-4 02:13:14 | 显示全部楼层

CRM:广东省人民医院团队首次证实,免疫联合化疗新辅助治疗对局部晚期EGFR突变肺癌安全有效

游客,您所在的用户组(游客)暂无权限查看回复内容,请微信注册本站
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

给我们建议|手机版|阳光肺科 ( 粤ICP备2020077405号-1 )

GMT+8, 2024-11-10 03:38

Powered by Discuz! X3.5

© 2001-2024 Discuz! Team.

快速回复 返回顶部 返回列表